There is limited information on the role of penicillin-binding proteins (PBPs) in the resistance of Acinetobacter baumannii to ␤-lactams. This study presents an analysis of the allelic variations of PBP genes in A. baumannii isolates. Twenty-six A. baumannii clinical isolates (susceptible or resistant to carbapenems) from three teaching hospitals in Spain were included. The antimicrobial susceptibility profile, clonal pattern, and genomic species identification were also evaluated. Based on the six complete genomes of A. baumannii, the PBP genes were identified, and primers were designed for each gene. 
the genes encoding PBPs in A. baumannii and to analyze their allelic variations in isolates susceptible or resistant to ␤-lactams.
(This work was presented in part as an oral presentation at the 8th International Symposium on the Biology of Acinetobacter in Rome, Italy, 2010.)
MATERIALS AND METHODS
Bacterial isolates. A total of 26 nonduplicate A. baumannii clinical isolates presenting different carbapenem susceptibility profiles were collected in three teaching hospitals in Spain: the University Hospital Marqués de Valdecilla, Santander (n ϭ 12), the Hospital Clínic, Barcelona (n ϭ 12), and the University Hospital Virgen Macarena, Seville (n ϭ 2) ( Table 1 ). The two isolates from the third hospital have been described previously (12) . These isolates were representative of the most prevalent clones in each institution. Presumptive identification of the isolates as A. baumannii was carried out by amplifying the complete open reading frame of the bla OXA-51 -like gene, which is considered chromosomally intrinsic to A. baumannii (31) , using primers OXA-69A and OXA-69B as described previously (18) . Both primers were also used to detect the presence of ISAba1 upstream of the bla OXA-51 -like gene (18) . Amplified rRNA gene restriction analysis (ARDRA), using the CfoI, AluI, MboI, RsaI, and MspI enzymes, was carried out as described previously (39) to confirm the genomic species identification of A. baumannii. The reference strain A. baumannii RUH-134 (11) was included as a control for both genomic identification and PCR amplification of PBP genes.
Testing of susceptibility to antimicrobial drugs. Tigecycline and colistin MICs were determined at the three participating centers by broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) guidelines (8) . The MICs of imipenem, meropenem, cefepime, ceftazidime, ceftriaxone, cefotaxime, aztreonam, amikacin, gentamicin, minocycline, and ciprofloxacin were also determined by microdilution for the isolates from the Hospital Clínic and the University Hospital Virgen Macarena, but for the isolates from the University Hospital Marqués de Valdecilla, the MICs of these drugs were determined with Etest strips according to the manufacturer's (AB bioMérieux, Solna, Sweden) recommendations,. The results for tigecycline were interpreted according to the U.S. Food and Drug Administration (FDA) breakpoints for Enterobacteriaceae (for susceptibility, Յ2 g/ml; for intermediacy, 4 g/ml; for resistance, Ն8 g/ml), and the results for the other antimicrobial agents tested were interpreted according to the CLSI breakpoints (9) . Pseudomonas aeruginosa ATCC 27853 and Escherichia coli ATCC 25922 were used as quality control strains.
Molecular typing by PFGE. The clonal relationships of the A. baumannii isolates were determined by pulsed-field gel electrophoresis (PFGE) using the ApaI restriction enzyme (Roche Diagnostics, Indianapolis, IN), as described elsewhere (34) . The restriction fragments were separated on 1% (wt/vol) agarose gels in 0.5% Tris-borate-EDTA (TBE) buffer in a CHEF-DR (contour-clamped homogeneous electric field-dynamically regulated) III Mapper electrophoresis system (Bio-Rad Laboratories, Richmond, CA) for 19 h at 14°C using a pulse ramping rate changing from 5 to 20 s at 6 V/cm. DNA fingerprints were interpreted as recommended by Tenover et al. (37) . The reference strains A. baumannii RUH-875 and RUH-134 (11), representatives of major international clones I and II, respectively, were also used as comparators.
Identification of PBP genes. The genes encoding PBPs were identified on the basis of the six complete genomes of A. baumannii that had been deposited in GenBank by the time this study was started. The following organisms were considered: A. baumannii strains AB0057 (accession no. NC_011586), ATCC 17978 (accession no. NC_009085), SDF (accession no. NC_010400), AYE (accession no. NC_010410), ACICU (accession no. NC_010611), and AB307-0294 (accession no. NC_011595). Consensus sequences were obtained for each PBP gene identified, and a series of primers for PCR amplification and sequencing was designed, as listed in Table S1 in the supplemental material. The A. baumannii genomes deposited in GenBank after the beginning of this study were also considered for comparison and analysis of the PBP genes. These genomes include those of A. baumannii strains AB056 (accession no. NZ_ADGZ01000571), AB058 (accession no. NZ_ADHA01000108), AB059 (accession no. NZ_ADHB01000264), AB900 (accession no. NZ_ABXK01000007), and ATCC 19606 (accession no. NZ_ACQB00000000).
Analysis of the PBP genes in A. baumannii clinical isolates. Genomic DNA from clinical isolates was extracted with InstaGene Matrix (Bio-Rad Laboratories, Hercules, CA) according to the manufacturer's recommendations. PBP genes were amplified by PCR under the following conditions: 95°C for 5 min, followed by 35 cycles of 95°C for 30 s, 55°C for 30 s, and 72°C for 1 to 3 min, according to the amplicon size, and finally 72°C for 7 min. PCR products were analyzed on 1% (wt/vol) agarose gels stained with ethidium bromide. PCR products were purified by using a High Pure PCR product purification kit (Roche Diagnostics, Mannheim, Germany). Bidirectional DNA sequencing was performed by Macrogen Inc. (Seoul, South Korea). Each PBP gene was named and classified on the basis of homology with other PBP sequences from different microorganisms deposited in GenBank, as well as by the recognition of conserved motifs. All PBP sequences were compared with those of A. baumannii ATCC 17978 (1).
Nucleotide sequence accession numbers. The nucleotide sequences of the PBP genes of the A. baumannii clinical isolates in this study have been deposited in the GenBank nucleotide sequence database and were assigned the following accession numbers, according to each PBP/MTG gene and strain: for ponA, JF746077 to JF746102; for mrcB, JF746103 to JF746128; for pbpA, JF745973 to JF745998; for ftsI, JF745999 to JF746024; for dacC, JF746025 to JF746050; for dacD, JF746051 to JF746074; for pbpG, JF746129 to JF746154; and for mtgA, JF745947 to JF745972.
RESULTS
PBP genes in A. baumannii. Seven PBP genes and one MTG gene were identified in the six A. baumannii genomes analyzed in this study (Table 2) . Four HMM PBPs were found: PBP1a (encoded by ponA), PBP1b (mrcB), PBP2 (pbpA or mrdA), and PBP3 (ftsI). According to their N-terminal domains, they were assigned to class A (PBP1a and PBP1b) or class B (PBP2 and PBP3). Sequence alignment revealed the five conserved motifs [EDXXFXXHXG, GXSTXX(M/Q)QXXK, RKXXE, KXXIXXYXN, and RXXXXL (where X is any amino acid)] of the glycosyltransferase N-terminal domain in both HMM class A PBPs (Fig. 1A) . In the C-terminal penicillin-binding (PB) domain, with transpeptidase activity, the residue following motif 3 [K(T/S)GT] was a threonine in class A PBPs (KTGTT for PBP1a and KSGTT for PBP1b) and an alanine in class B PBPs (KTGTA), as expected (Fig. 1B) . The HMM class A PBPs, PBP1a and PBP1b, are the major transglycosylases-transpeptidases in A. baumannii and are probably involved in the elongation of non-cross-linked glycan chains of peptidoglycan.
The presence of an aspartic acid residue at the third position of motif 2 (SXD) in the active site of PBP2 (pbpA) and the presence of an asparagine residue at the same position in PBP3 confirmed the classification of these PBPs into subclasses B2 and B3, respectively (Fig. 1C) . Both PBP2 and PBP3 are monofunctional transpeptidases. PBP2 is a member of subclass B2, a group of proteins involved in cell elongation. PBP3, as a member of subclass B3, is probably associated with cell division. The fstI gene was localized in the A. baumannii genomes in an operon with the mraW, mraY, ftsL, murE, and murF genes, which are associated with the divisome. MtgA (encoded by mtgA) is a monofunctional transglycosylase with a glycosyltransferase domain similar to those of PBP1a and PBP1b.
Three LMM PBPs have been found in A. baumannii: PBP5/6 (encoded by dacC), PBP6b (dacD), and PBP7/8 (pbpG). These LMM PBPs are associated with cell separation and the maturation or recycling of peptidoglycan. Analysis of the genes encoding PBP5 and PBP6 in A. baumannii genomes showed that they are identical at the nucleotide and amino acid levels. Thus, this PBP is referred to as PBP5/6 (dacC). This PBP and PBP6b (dacD) were classified as class C type 5 PBPs, and both are presumably D-Ala-D-Ala-carboxypeptidases. PBP7/8 (pbpG) is a class C type 7 PBP with putative endopeptidase activity. No class C type 4 PBP genes seem to be present in A. baumannii.
Hot spot mutations in PBP genes and ␤-lactam resistance. The 26 clinical isolates were identified as A. baumannii by ARDRA, and all isolates carried a bla OXA-51 allele (Table 1) . PFGE profile analysis revealed that the 26 isolates were categorized into 11 different clones. All A. baumannii isolates were susceptible to colistin and tigecycline, with MICs ranging from 0.25 to 1 g/ml and 0.5 to 1 g/ml, respectively. Minocycline also showed good coverage against the A. baumannii isolates tested (73.1% susceptibility; MIC at which 50% of isolates were inhibited [MIC 50 ], 2 g/ml). High resistance rates were observed for expanded-spectrum cephalosporins (MIC 50 , Ն32 g/ml), cefepime (MIC 50 , Ն32 g/ml), and aztreonam (MIC 50 , Ͼ16 g/ml). The MICs of imipenem and meropenem ranged from 0.25 to Ͼ32 g/ml, and for 53% of the isolates, the MICs of both these antimicrobial agents were Ͼ32 g/ml. The majority of the isolates were resistant to ciprofloxacin (MIC 50 , Ͼ2 g/ml) and aminoglycosides (MIC 50 s, Ͼ8 g/ml for gentamicin and Ͼ16 g/ml for amikacin). All the A. baumannii isolates resistant to carbapenems (n ϭ 14) carried the plasmid-borne carbapenemase gene bla or the insertion sequence ISAba1 upstream of the chromosomal bla OXA-51 -like gene and/or AmpC (data not shown).
Analysis of the nucleotide sequences of the seven PBP genes and one MGT gene in the A. baumannii clinical isolates revealed specific hot spot mutation regions in all genes. However, most of the allelic variations observed were silent mutations (data not shown). The main changes in the different PBP genes relative to the sequences of strain ATCC 17978 are shown in Table 3 . Although a few mutations were found in the amino acid sequences of the PBPs, none of these mutations could be related to ␤-lactam resistance. The observed changes in the amino acid sequence were associated with specific clonal patterns, and in general, the same mutations were observed in organisms from the different hospitals as well as in the 10 genomes already sequenced (Table 4) . Interestingly, comparison of the amino acid consensus sequence corresponding to each PBP gene in the A. baumannii genomes deposited in GenBank with the corresponding amino acid consensus sequence of the 26 A. baumannii clinical isolates showed that these genes were highly conserved (identity, 99.6% to 100.0%).
In two isolates (HUMV-1319 and HUMV-5118) of an endemic carbapenem-resistant clone (MIC, Ͼ32 g/ml) from one of the participating centers, PCR amplification of the carboxypeptidase PBP6b gene showed a fragment of 2,410 bp instead of the expected 1,320 bp. Sequencing of this amplicon indicated the presence of an insertion sequence (IS) disrupting the PBP6b gene. This IS was identical to an IS30 family transposase found in the genome of A. baumannii strain ACICU and was similar to ISAba125, differing only in His 222 Tyr codons in the transposase gene. Two imperfect inverted repeats (IR-L [AAACTTGAAGTCGACA] and IR-R [TGTCGCACCTCA TGTTT]) bordering the transposase gene were also identified. The IS was not found in the carO gene in these two isolates (data not shown).
DISCUSSION
PBPs are involved in the metabolism of peptidoglycan, an essential component of the bacterial cell wall (33) . ␤-Lactams mimic the D-Ala-D-Ala dipeptide and act as suicide inhibitors binding covalently to the PBPs (45) . Inhibition of PBPs causes instability in the cell wall, resulting in growth inhibition or lysis (42) . In this study, seven PBP genes and one MGT gene were found in the genomes of several A. baumannii strains, encoding PBP1a, PBP1b, PBP2, PBP3, PBP5/6, PBP6b, PBP7/8, and MtgA. The amino acid sequences of these PBPs in the A. baumannii clinical isolates were compared with those in strain ATCC 17978. This strain was isolated in the early 1950s (1), prior to the development of the majority of the antimicrobial agents used in clinical practice. This comparison showed that PBP genes are highly conserved in all A. baumannii strains analyzed. The few point mutations observed could not be associated with carbapenem resistance, since they were found in both susceptible and resistant strains. Some point mutations were observed in specific isolates, especially in the genome of strain SDF (Table 4) , a multisusceptible A. baumannii strain. It is most probable that these variations are associated with clonal patterns. PBPs with low affinity for ␤-lactams had been described for Acinetobacter spp. (13, 26, 38) . Gehrlein et al. (13) 78 kDa) , respectively, but the last PBP did not correlate with PBP7/8 (36.86 kDa). They also observed that imipenem could select in vitro for a resistant A. baumannii mutant showing a complex reorganization of PBPs. Because no alterations in outer membrane proteins (OMPs) or in ␤-lactamase production were detected in the imipenem-resistant mutant, the authors associated the alterations in PBP profiles with the observed imipenem resistance. In another study, Obara and Nakae (26) evaluated 12 imipenem-susceptible strains of Acinetobacter calcoaceticus and detected six PBP bands of 94 (PBPla), 92 (PBPlb), 86 (PBPlc), 74 (PBP2), 59 (PBP3), and 42 (PBP4) kDa. In vitro-selected mutants resistant to cefoxitin, cefoperazone, or ceftazidime showed reduced expression of porins, as well as alterations in PBP expression and/or affinity for ␤-lactams. In another study, an imipenem-resistant nosocomial strain of A. baumannii showing PBPs with low affinity for ␤-lactamase inhibitors, especially clavulanic acid, was reported (38) . This study also showed that sulbactam bound to PBPs better than tazobactam, even in imipenem-resistant strains, which may explain the satisfactory in vitro activity of sulbactam against some multidrug-resistant A. baumannii isolates (22, 28) .
Fernández-Cuenca et al. (12) used 12% SDS-PAGE gels marked with 125 I-labeled ampicillin to evaluate the PBP profiles of two groups of A. baumannii isolates with imipenem and meropenem MICs of 0.25 to 2 g/ml and 4 to 32 g/ml, respectively. Isolates HUS-31 and HUS-457, included in the present study, are representative of these two groups, respectively. Isolates with carbapenem MICs of Ն4 g/ml showed reduced expression of a 73.2-kDa PBP named PBP2 (which may correspond to the PBP2 identified in this study [74.42 kDa]), associated with the production of several ␤-lactamases, including oxacillinases (which has been confirmed in the present study), and, in some isolates, with the loss of a 22.5-kDa porin. We have not observed any mutations in PBP2 (or any other PBP) of strain HUS-457, suggesting that regulatory mechanisms could be involved in the reported decreased expression of the 73.2-kDa protein in this isolate.
An IS has been found to disrupt the dacD gene (encoding PBP6b) in two isolates of a carbapenem-resistant endemic (43) evaluated proteome regulation in an imipenem-resistant A. baumannii strain under antibiotic stress conditions. They observed that the levels of RND family transporters (AdeABC and AdeJIK), the PBP genes ponA (PBP1a), ftsI (PBP3), and dacC (PBP5/6), and, noticeably, AmpC ␤-lactamase were increased in the presence of imipenem. In contrast, repression of the OMPs OmpA and OmpW was observed under the same conditions. These results suggest that together such mechanisms contribute to imipenem resistance in A. baumannii.
In the presence of efficient alternatives, such as CHDL production and/or porin loss, the selective pressure of ␤-lactams against PBPs in A. baumannii may be insufficient to select for structural changes that are directly involved in ␤-lactam resistance. On the other hand, it is possible that other complex mechanisms associated with the regulation of PBP genes, as well as posttranscriptional events, could cause ␤-lactam resistance in this pathogen. Our findings may represent a first step toward understanding of the actual role of the PBPs in the complex resistance of A. baumannii to ␤-lactams.
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